Clinical TrialsSearch results
Number of results: 885
Recruiting
- Bioequivalence study of JTE-052
- atopic dermatitis
- Mitsui Hironori
- 2024-03-15
Recruiting
- A Phase 3, Open-label Study Assessing Self-administered Rocatinlimab (AMG 451) in Subjects With Moderate-to-severe AD
- Atopic Dermatitis
- Chen Sarah
- 2024-04-23
Recruiting
- A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD
- Atopic Dermatitis
- Jain Neal
- 2023-07-01
Other
- Study of SNPs effect of Cytochrome P450 and Vitamine K related enzyme on PK/PD of warfarine
- atrial fibrillarion, pulmonary embolism, deep vein thronbosis, heart failure, stroke and other cardiovascular diseases
- St. Marianna University School of Medicine
- 2008-02-28
Other
- Investigation of the Optimal Treatment Strategy for Atrial Fibrillation in Japan -The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) Study-
- Atrial Fibrillation
- The J-RHYTHM Investigators
- 2005-09-08
Other
- A multicenter study on warfarin use and optimal anticoagulation levels for prevention of cardiogenic embolism in Japanese patients with atrial fibrillation: J-RHYTHM Registry
- atrial fibrillation
- The Japanese Society of Electrocardiology
- 2009-01-05
Not yet recruiting
- Multidisciplinary Approach after Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure
- Atrial fibrillation
- Yagishita Atsuhiko
- 2023-12-06
Completed
- Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone TAVI - In Atrial Fibrillation
- Atrial Fibrillation
- Watanabe Yusuke
- 2019-02-21
Other
- A Randomized Study of Angiotensin II Type 1 Receptor Blocker vs Dihydropidine Ca Antagonist for Treatment of Paroxysmal Atrial Fibrillation in Patients with Hypertension
- Atrial Fibrillation with Hypertension
- The J-RHYTHM II Investigators
- 2006-07-10
Other
- A study to evaluate Patisiran in patients with transthyretin-type amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy)
- ATTR amyloidosis with cardiomyopathy
- Alnylam Pharmaceuticals, Inc
- 2021-05-12